查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
外泌體的全球市場 - 市場規模，預測，實驗，趨勢 (2024年)
市場調查報告書
商品編碼
1550796

外泌體的全球市場 - 市場規模，預測，實驗，趨勢 (2024年)

The Global Exosome Market - Market Size, Forecast, Trials and Trends, 2024
出版日期: | 出版商: BioInformant | 英文 351 Pages | 訂單完成後即時交付

價格
簡介目錄

摘要整理

外泌體是源自內體的細胞外囊泡（EV），其大小為 30 至 150 奈米。外泌體幾乎由所有細胞類型分泌，透過攜帶被受體細胞選擇性攝取的細胞特異性蛋白質、脂質和核酸，在細胞間通訊中扮演重要角色。

外泌體技術的最新進展正在促進外泌體在液體活檢、精準醫學和再生醫學中的廣泛使用。癌症來源的外泌體因其控制血管生成、轉移和免疫的能力而特別有價值，對於癌症檢測、診斷和治療選擇極為重要。

外泌體貨物不僅提供了有關癌症預後的知識，還提供了有關心血管疾病、腎臟疾病、神經退化性疾病和代謝疾病等各種疾病預後的知識。外泌體中存在大量生物分子的發現激發了人們對其作為癌症生物標記進行檢測、監測和治療的廣泛研究。

外泌體存在於血清、血漿、尿液和唾液等許多生物體液中，使其成為微創診斷的理想選擇。它也可作為預後指標和治療效果的預測因子。此外，外泌體的治療應用也正在研究中。例如，外泌體可以被設計為攜帶治療性siRNA或蛋白質，用於標靶治療由缺陷或缺陷分子引起的疾病。源自間質幹細胞（MSC）的外泌體已顯示出減少發炎、防止疤痕組織形成和調節免疫反應的潛力。

曾經被低估的外泌體領域現在正在迅速發展。最近的論文重點介紹了美國作者和中國研究人員的工作，尤其是卡羅林斯卡學院和 Unicyte AG 的 Susanne Gabrielsson 博士在相關科學文獻中處於領先地位。

BioInformant 的全球策略報告詳細介紹了快速成長的外泌體市場，包括專利、撥款、出版物和臨床試驗趨勢。它還研究了行業聯盟、併購 (M&A) 和融資，並包括競爭格局和到 2030 年的市場預測。

使用外泌體的診斷和治療藥物的數量正在擴大，目前有388項臨床試驗正在進行中。儘管外泌體療法尚未獲得上市批准，但前五種產品預計將於 2029 年上市。與傳統療法相比，外泌體具有明顯的優勢，包括標靶遞送、減少副作用和逃避免疫檢測。

除了醫療用途外，外泌體還用於化妝品中，以促進皮膚再生、傷口癒合、疤痕矯正和頭髮再生。兩種基於外泌體的診斷方法已獲得美國 FDA 的快速批准。

這份綜合報告提供以下資訊：

  • 市場分析：外泌體治療/診斷、產品/服務、製造技術、化妝品應用
  • 外泌體療法的臨床試驗管道（包括天然外泌體和人工外泌體）
  • 已批准且即將推出的利用外泌體診斷的產品
  • 臨床試驗活動：按類型、地區、階段和投資者分類
  • 關鍵產業指標分析：科學論文、專利、經費、臨床試驗等。
  • 重大融資事件（包括併購、融資事件、聯合開發協議和首次公開發行）
  • 策略夥伴關係與競爭考量因素
  • 市場規模（按細分市場、地區）和預測（截至 2030 年）
  • 產業趨勢與未來方向

本報告旨在為開發外泌體治療/診斷、研究產品、製造技術、化妝品和 RTU（即用型）外泌體的公司提供市場資訊。外泌體市場擠滿了競爭對手，因此這份報告提供了寶貴的資源，讓您無需花費無數時間進行研究即可了解情況並抓住機會。

目錄

第1章 調查概要

第2章 外泌體的生物學和功能:概要

  • 外泌體結構
    • 外泌體的分子含有量
    • 外泌體的薄膜和內腔的結構要素
    • 由於外泌體的來源的分類
    • 合成外泌體
  • 細胞治療和基因治療的差異
  • 從細胞療法外泌體療法的轉變
  • 今後10年的外泌體

第3章 外泌體工程:新的技術平台

  • 內部修飾
    • 分離前內部修飾方法
    • 孵化
    • 遺傳基因編輯
    • 分離後內部修飾方法
  • 表面改性
    • 親代細胞的表面修飾
    • 直接表面改性
    • 外泌體內分子的展示
  • 內部修改
    • 分離前的內部修改方法
    • 分離後的修改方法
  • 表面/內部修飾的外泌體
    • 親水性物質裝入外泌體腔的範例

第4章 外泌體相關科學出版刊物

  • 外泌體診斷方法和治療的發表趨勢
  • 關於治療性外泌體關鍵技術的 PubMed 出版物
  • 來自 PubMed 的外泌體分離與純化技術文章
  • 關於脂質奈米粒子和外泌體作為藥物載體的 PubMed 文章
  • 外泌體出版物的分佈：依疾病類型
  • 外泌體出版品：依癌症類型分類

第5章 外泌體專利概要

  • 外泌體的專利公開的轉變
  • 外泌體專利:治療用和診斷用
  • 外吐小體專利申請:外吐小體的供給來源
  • 專利/專利申請:分離·精製各技術
  • 專利/專利申請:貨物類別
  • 專利/專利申請:貨物的裝載各方法
  • 專利/專利申請:各治療領域
  • 外泌體專利的主要受讓人
    • 取得專利的分離·製作技術類型:各申請人
    • 受讓人使用的貨物的種類
    • 貨物的裝載方法:各申請人
    • 治療領域:各申請人
    • 受讓人的類別
  • 外吐小體專利的申請數量:各管轄地區
  • 外泌體專利的申請人
  • 外泌體專利的發明者
  • 外吐小體專利的所有者
  • 外泌體專利法律上的地位

第6章 外泌體:臨床試驗的形勢

  • 外泌體臨床試驗:研究各階段
  • 外泌體臨床試驗:各資金提供者類型
  • 外泌體臨床試驗:各技術
  • 利用外泌體治療疾病的臨床試驗現狀
  • 使用外泌體進行診斷研究的臨床試驗
  • 主要外泌體研發公司
  • 臨床前開發中的外泌體療法

第7章 外泌體分離/精製技術:概要

  • 超離心分離 (UC)
    • 刻度超離心分離
    • 密度傾斜超離心分離 (DGU)
  • 超過濾 (UF)
    • 串聯結構的超過濾
    • 連續超過濾
  • 粒徑篩析層析法 (SEC)
  • 聚合物沉澱法
  • 免疫親和性理解法
  • 適配體為基礎的方法
  • 微流體技術

第8章 外泌體企業的專利技術平台

  • 所選外泌體技術平台的說明
    • AGLE-102
    • Hybridosome
    • AB126
    • CAP-1002 (Deramiocel)
    • REGENT
    • ExoFlo
    • DeliverEX
    • EXOVEX
    • ExoSCRT
    • LEAP
    • ExoDx
    • EXPLOR
    • Exo-Target

第9章 外泌體工程技術:概要

  • 孵化法
  • 轉染法
  • 超音波處理法
  • 電穿孔法
  • 押出法
  • 凍結融化法
  • 遺傳因子工程學的手法

第10章 外泌體的治療的應用:概要

  • 外泌體治療領域的主要企業
    • Nano24EXO-CD24 (OBCTCD24)
    • The Hemopurifier
    • Carmine Therapeutics的REGENT
    • Ciola的外泌體客制化技術
    • Capricor Therapeutics的CAP-1002 (Deramioce)
    • ILIAS Biologics的EXPLOR
    • Aruna Bio的AB126
    • Aegle Therapeutics的AGLE-102
    • OmniSpirant Therapeutics的OmniSomes
    • Exogenus Therapeutics的EXO-101
    • RION的精製外泌體產品 (PEP)

第11章 外泌體的診斷的應用

  • 診斷用途的優點
  • 診斷重點的主要適應症
  • 最常見的標的外泌體生物標記
    • 診斷用途的外泌體蛋白質
    • 癌症診斷藥的外泌體miRNA
  • 診斷用外泌體的研究
  • 外泌體診斷藥的開發的主要企業
    • BioFluidica 的 LiquidScan
    • ExoCan 的 ExoEnrich
    • Exosome Diagnostics, Inc. 提供的 ExoDx 前列腺測試
    • Exosome Science 的 Tausome 測試
    • 使用 Exosomics SpA 進行癌症診斷
    • Guardant Health 的 Guardant360 CDx
    • Mursla Bio 的肝癌檢測研究
    • NanoSomiX BDE 生物標記檢測
    • Theoria Science 的 ExoScreen 檢測

第12章 美容的外泌體的應用

  • 美容外泌體治療
    • 臉部回春的外泌體
    • 育髮的外泌體
    • 除疤的外泌體
    • 豐胸手術的外泌體
  • 美容目的外泌體的供給來源
  • 皮膚科學相關的外泌體的科學
  • 主要業者與產品
  • 受歡迎的外泌體為基礎的美容
    • AnteAGE Pro系統
    • Cartessa的ExoCR
    • ELEVAI Labs的ELEVAI enfinity
    • Exoceuticals的EXO PLUS
    • Kimera Labs的Vive
    • RION Aesthetics的CALM Serum
    • ExoCoBio的ASCE Exosomes

第13章 外吐小體領域的交易與資金籌措

  • 對外泌體企業的創業投資資金
    • EXO Biologics
    • Exogenus Therapeutics
    • INEXOPLAT
    • Mantra Bio
    • Anjarium Biosciences
    • Evox Therapeutics, Ltd.
    • ILIAS Biologics
    • ExoCoBio, Inc.
    • Aegle Therapeutics
    • Evox Therapeutics
    • Evox Therapeutics
    • Codiak BioSciences
    • Codiak BioSciences
    • Exosome Diagnostics
    • Exosome Diagnostics, Inc
    • EXO生物製劑
  • 外吐小體領域的夥伴關係契約
    • Cytiva和Rooster Bio
    • SomesTech和ConvEyXO
    • RoosterBio, Inc.和FUJIFILM Diosynth Biotechnologies
    • Evox Therapeutics和Eli Lilly
    • Exopharm和Astellas
    • Univercells Technologies和RoosterBio
    • AgeX Therapeutics和UCI
    • VivaZome和La Trobe University
    • Evotec SE和Curexsys GmbH
    • Bio-Techne和QIAGEN
    • InnoCan Pharma和Recipharms
    • Codiak BioSciences和Sarepta
    • Evox Therapeutics和Takeda
    • PureTech和Roche
    • Evox Therapeutics和Boehringer Ingelheim
    • Sarpeta Therapeutics和Codiak Biosciences
    • Navigo Proteins和MDimune
    • Jazz Pharmaceuticals和Codiak BioSciences
    • Exosome Diagnostics和Intezyne
    • Evox Therapeutics和Boehringer Ingelheim
  • 企業收購交易
    • ExoCoBio和BENEV
    • Evox Therapeutics和Codiak Biosciences' Technology
    • Lonza和Exosomics
    • Lonza和Codiak Biosciences
    • Bio-Techne Corporation和Exosome Diagnostics
    • Lonza和HansaBioMed
  • 授權交易
    • EVerZom和Erganeo
    • Elevai Labs和Yuva Biosciences
    • TOPPAN和Dai Nippon Toryo
    • Carnegie Mellon University (CMU和)Coya Therapeutics
    • INOVIQ, Ltd.和ResearchDx, Inc.
    • ATUM和Codiak BioSciences
    • Johns Hopkins University和Capricor Therapeutics
    • Evox Therapeutics和Eli Lily
    • Codiak BioSciences和Sarepta
    • VivaZome Therapeutics和University of Adelaide
    • Evox Therapeutics和Takeda
    • CEVEC和Evox Therapeutics
    • Orgenesis和Excella Bio
    • System Biosciences和QIAGEN
    • PureTech Health和3D Biotechnologies
  • 首次股票公開發行
    • Elevai Labs
    • Codiak Biosciences
    • Codiak Biosciences
    • Codiak BioSciences

第14章 外泌體市場分析

  • 外泌體治療藥的市場
  • 全球RTU (Ready-to-Use) 精製外泌體市場:各類型
    • 外泌體的市場規模:親代細胞類別
  • 外泌體診斷藥的市場
  • 全球外泌體技術市場:各產品種類
  • 全球外泌體為基礎的美容品 (化妝品) 市場
  • 外泌體的市場全體
  • 外泌體療法的市場牽引角色

第15章 外泌體市場競爭企業的簡介

  • 101 Bio
  • Abbexa, Ltd.
  • AcouSort AB
  • Aegle Therapeutics
  • Aethlon Medical, Inc.
  • Akrivis Health Care Pvt., Ltd.
  • AM BioTech
  • AMS Biotechnology, Ltd. (AMSBIO)
  • AnteAGE
  • Aposcience AG
  • Aruna Bio
  • BENEV Company, Inc. (ExoCoBio)
  • BioCat GmbH
  • BioFluidica
  • Biological Dynamics, Inc.
  • Biorbyt, Ltd.
  • Bioscience Institute
  • Biosynth International, Inc.
  • BreStem Therapeutics, Inc.
  • Capricor Therapeutics
  • Carmine Therapeutics
  • Cellarcus Biosciences, Inc.
  • Cell Care Therapeutics
  • Cells for Cells
  • Cell Guidance Systems, Ltd.
  • Ciloa
  • ConvEyXO
  • Craif, Inc.
  • Creative Bioarray
  • Creative Biostructure
  • Creative Biolabs
  • Creative Medical Technology Holdings, Inc.
  • Creative Proteomics
  • CUSABIO Technology LLC
  • Diadem Biotherapeutics
  • Direct Biologics
  • Elevai Labs, Inc.
  • Entelexo Biotherapeutics
  • EriVan Bio
  • EVerZom
  • Evolutionary Biologics, Inc.
  • Evomic Science LLC
  • Evox Therapeutics, Ltd.
  • EXO Biologics
  • ExoCan Healthcare Technologies Pvt., Ltd.
  • Exocel Bio
  • Exogenus Therapeutics
  • Exokeryx, Inc.
  • ExoProTher Medical
  • ExoQure
  • EXORPHIA, Inc.
  • ExosomeDx (biotechne)
  • ExosomePlus
  • Exosome Sciences
  • ExoStemTech Co., Ltd.
  • ExoVectory
  • ExSURE Pvt. Ltd.
  • Florica Therapeutics
  • HansaBioMed Life Sciences, Ltd.
  • ILIAS Biologics, Inc.
  • INEXOPLAT, Inc.
  • Innocan Pharma
  • Innovex Therapeutics, SL
  • INOVIQ, Ltd.
  • Irazu Oncology
  • Izon Science, Ltd.
  • Kimera Labs, Inc.
  • Leading Biology, Inc.
  • LifeSpan Biosciences, Inc.
  • Lonza Group, Ltd.
  • Mantra Bio
  • Mercury Bio
  • Mercy Bioanalytics
  • Micregen, Ltd.
  • Microgentas
  • miR Scientific
  • Liver EV Liquid Biopsy Platform
  • MyBioSource, Inc.
  • Nano 24 (OBCDCT24)
  • NanoSomiX, Inc.
  • Nanovex Biotechnologies
  • NeurExo Sciences
  • NeuroDex, Inc.
  • Norgen Biotek Corporation
  • Novaxomx GmbH
  • Novus Biologicals
  • NurExone Biologic, Inc.
  • Oasis Diagnostics Corporation
  • NX Prenatal, Inc.
  • OmniSpirant Therapeutics
  • OncoXome, Inc.
  • Paracrine Therapeutics Pte, Ltd.
  • QIAGEN
  • Reactive Medical Labs
  • ReNeuron
  • RION Aesthetics, Inc.
  • Rivela Diagnostics
  • RoosterBio, Inc.
  • ShiftBIO
  • SOL Bio Corporation
  • SomesTech
  • Stem Cell Medicine, Ltd.
  • System Biosciences
  • Theoria Science, Inc.
  • TheraXyte
  • Thermo Fisher Scientific
  • TheraXyte Bioscience
  • The Tiny Cargo Company
  • TransGen Biotech, Co., Ltd.
  • Tymora Analytical
  • Unicyte AG
  • Urvogelbio Pvt, Ltd.
  • Versatope Therapeutics
  • VesiCURE Therapeutics
  • Vesigen Therapeutics, Inc.
  • VivaZome Therapeutics
  • ZEO ScientifiX, Inc.
  • Xosomix

圖的索引

表的索引

簡介目錄

EXECUTIVE SUMMARY

Exosomes are extracellular vesicles (EVs) originating from endosomes, with sizes ranging from 30 to 150 nanometers. Secreted by nearly all cell types, exosomes play a key role in cell communication by carrying cell-specific proteins, lipids, and nucleic acids that are selectively absorbed by recipient cells.

Recent advancements in exosome technology are driving growth in their application across liquid biopsy, precision medicine, and regenerative medicine. Cancer-derived exosomes, in particular, are valuable for their ability to regulate angiogenesis, metastasis, and immunity, making them crucial for cancer detection, diagnosis, and treatment selection.

Exosome cargos offer prognostic insights for various diseases, including cardiovascular, renal, neurodegenerative, and metabolic disorders, as well as cancer. The discovery of numerous biomolecules within exosomes has spurred extensive research into their use as cancer biomarkers for detection, monitoring, and treatment.

Exosomes are present in many biofluids such as serum, plasma, urine, and saliva, making them ideal for minimally invasive diagnostics. They also serve as prognostic indicators and predictors of treatment responses. Furthermore, exosomes are being investigated for therapeutic use. For instance, exosomes can be engineered to carry therapeutic siRNA or proteins for targeted treatment of diseases caused by defective or missing molecules. Mesenchymal stem cell (MSC) derived exosomes have shown potential in reducing inflammation, preventing scar tissue formation, and modulating immune responses.

The exosome field, once underappreciated, is now rapidly evolving. Recent publications highlight the significant contributions of U.S. authors and Chinese researchers, with Dr. Susanne Gabrielsson from the Karolinska Institutet and Unicyte AG leading in relevant scientific literature.

BioInformant's global strategic report details the burgeoning exosome market, including trends in patents, grants, publications, and clinical trials. It covers industry partnerships, M&A activities, and financing, with insights into the competitive landscape and market forecasts through 2030.

Exosome-based diagnostics and therapeutics are expanding, with 388 clinical trials currently underway. Although no exosome therapeutics have received marketing approval yet, the first five products are anticipated by 2029. Exosomes offer promising advantages over traditional therapies, including targeted delivery, reduced side effects, and avoidance of immune detection.

In addition to medical applications, exosomes are also being used within cosmetics to promote skin rejuvenation, wound healing, scar revision, and hair restoration. Two exosome-based diagnostics have already received Fast Track approval from the U.S. FDA.

This comprehensive report provides:

  • Market analysis for exosome therapeutics, diagnostics, product/services, manufacturing technologies, and cosmetic applications
  • The clinical trial pipeline for exosome therapeutics, including both naive and engineered exosomes
  • Approved and forthcoming products leveraging exosome diagnostics
  • Clinical trial activity by type, region, phase, and sponsor
  • Analysis of key industry metrics, including scientific publications, patents, grants, and clinical trials
  • Key funding events, including M&A, financing events, co-development agreements, and IPOs
  • Strategic partnerships and competitive insights
  • Market size figures, broken down by market segment and geography, with forecasts through 2030
  • Industry trends and future directions

This report is designed to inform market competitors who are developing exosome therapeutics, diagnostics, research products, manufacturing technologies, cosmeceuticals, and of course, ready-to-use exosomes. With the competitive nature of the exosome market, this report offers a valuable resource to stay informed and seize opportunities, without spending countless hours on research.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Target Demographic
  • 1.3. Report Sources
  • 1.4. Purpose of the Report
  • 1.5. Executive Summary
  • 1.6. Introduction

2. BIOLOGY & FUNCTIONS OF EXOSOMES: AN OVERVIEW

  • 2.1. Structure of an Exosome
    • 2.1.1. Molecular Contents of Exosomes
      • 2.1.1.1. Proteins in Exosomes
      • 2.1.1.2. Lipid Contents of Exosomes
      • 2.1.1.3. Nucleic Acids in Exosomes
    • 2.1.2. Membrane and Lumen Components of Exosomes
    • 2.1.3. Classification of Exosomes by Origin
      • 2.1.3.1. Natural Exosomes
        • 2.1.3.1.1. Isolation of Natural Exosomes
      • 2.1.3.2. Modified Exosomes
        • 2.1.3.2.1. Types of Therapeutic Cargos Loaded into Exosomes
        • 2.1.3.2.2. Biomedical Applications of Engineered Exosomes
    • 2.1.4. Synthetic Exosomes
  • 2.2. Differences between Cell Therapy and Gene Therapy
  • 2.3. The Shift from Cell Therapy to Exosome Therapy
  • 2.4. Exosomes in the Next Ten Years

3. EXOSOME ENGINEERING: A NEW TECHNOLOGY PLATFORM

  • 3.1. Interior Modification
    • 3.1.1. Pre-Isolation Interior Modification Methods
    • 3.1.2. Incubation
    • 3.1.3. Gene Editing
    • 3.1.4. Post-Isolation Interior Modification Methods
  • 3.2. Surface Modifications
    • 3.2.1. Surface Modification through Parent Cell
    • 3.2.2. Direct Surface Modification
    • 3.2.3. Displayed Molecules in Exosomes
  • 3.3. Interior Modification
    • 3.3.1. Pre-Isolation Interior Modification
    • 3.3.2. Post-Isolation Modification Methods
  • 3.4. An Exosome Showing Modified Surface and Modified Interior
    • 3.4.1. Examples of Hydrophilic Cargo Loaded into Exosome Lumen

4. SCIENTIFIC PUBLICATIONS ON EXOSOMES

  • 4.1. Publication Trends of Exosome Diagnostics and Therapeutics
  • 4.2. PubMed Publications on Therapeutic Exosomes by Loading Technology
  • 4.3. PubMed Papers on Exosome Isolation & Purification by Technology
  • 4.4. PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
  • 4.5. Distribution of Exosome Publications by Disease Type
  • 4.6. Exosome Publications by Cancer Type

5. EXOSOME PATENTS: AN OVERVIEW

  • 5.1. Exosome Patent Publications over Time
  • 5.2. Exosome Patents: Therapeutic vs. Diagnostics
  • 5.3. Exosome Patent Applications by Exosome Source
  • 5.4. Patents/Patent Applications by Isolation/Purification Technologies
  • 5.5. Patents/Patent Applications by Type of Cargo
  • 5.6. Patents/Patent Applications by Cargo Loading Methods
  • 5.7. Patents/Patent Applications by Therapy Area
  • 5.8. Leading Assignees of Exosome Patents
    • 5.8.1. Types of Patented Isolation/Preparations Technologies by Assignees
    • 5.8.2. Types of Cargos Employed by Assignees
    • 5.8.3. Cargo Loading Methods by Assignees
    • 5.8.4. Therapy Areas by Assignees
    • 5.8.5. Assignee Categories
  • 5.9. Exosome Patent Applications by Jurisdiction
  • 5.10. Exosome Patent Applicants
  • 5.11. Exosome Patent Inventors
  • 5.12. Exosome Patent Owners
  • 5.13. Legal Status of Exosome Patents

6. EXOSOMES: CLINICAL TRIAL LANDSCAPE

  • 6.1. Exosome Clinical Trials by Phase of Study
  • 6.2. Exosome Clinical Trials by Funder Type
  • 6.3. Exosome Clinical Trials by Technology
  • 6.4. Current Status of Clinical Trials using Exosomes in Treating Diseases
  • 6.5. Clinical Trials using Exosomes for Diagnostic Studies
  • 6.6. Major Exosome R&D Companies
  • 6.7. Exosome Therapeutics in Preclinical Development

7. EXOSOME ISOLATION/PURIFICATION TECHNOLOGIES: BRIEF OVERVIEW

  • 7.1. Ultracentrifugation (UC)
    • 7.1.1. Differential Ultracentrifugation
    • 7.1.2. Density Gradient Ultracentrifugation (DGU)
  • 7.2. Ultrafiltration (UF)
    • 7.2.1. Tandem-Configured Ultrafiltration
    • 7.2.2. Sequential Ultrafiltration
  • 7.3. Size Exclusion Chromatography (SEC)
  • 7.4. Polymer Precipitation Method
  • 7.5. Immunoaffinity Capture Method
  • 7.6. Aptamer-Based Method
  • 7.7. Microfluidic Technique

8. PROPRIETARY TECHNOLOGY PLATFORMS OF EXOSOME COMPANIES

  • 8.1. Description of Select Exosome Technology Platforms
    • 8.1.1. AGLE-102
    • 8.1.2. Hybridosome
    • 8.1.3. AB126
    • 8.1.4. CAP-1002 (Deramiocel)
    • 8.1.5. REGENT
    • 8.1.6. ExoFlo
    • 8.1.7. DeliverEX
    • 8.1.8. EXOVEX
    • 8.1.9. ExoSCRT
    • 8.1.10. LEAP
    • 8.1.11. ExoDx
    • 8.1.12. EXPLOR
    • 8.1.13. Exo-Target

9. EXOSOME ENGINEERING TECHNOLOGIES: AN OVERVIEW

  • 9.1. Incubation Method
  • 9.2. Transfection Method
  • 9.3. Sonication Method
  • 9.4. Electroporation Method
  • 9.5. Extrusion Method
  • 9.6. Freeze/Thaw Method
  • 9.7. Genetic Engineering Method

10. THERAPEUTIC APPLICATIONS OF EXOSOMES: A BRIEF OVERVIEW

  • 10.1. Key Players in the Exosome Therapeutic Space
    • 10.1.1. EXO-CD24 from Nano24 (OBCTCD24)
    • 10.1.2. The Hemopurifier
      • 10.1.2.1. Hemopurifier in Cancer
      • 10.1.2.2. Hemopurifier in Infectious Diseases
    • 10.1.3. REGENT from Carmine Therapeutics
    • 10.1.4. Exosome Customization Technology from Ciola
    • 10.1.5. CAP-1002 (Deramioce) from Capricor Therapeutics
    • 10.1.6. EXPLOR from ILIAS Biologics
    • 10.1.7. AB126 from Aruna Bio
    • 10.1.8. AGLE-102 from Aegle Therapeutics
    • 10.1.9. OmniSomes from OmniSpirant Therapeutics
    • 10.1.10. EXO-101 from Exogenus Therapeutics
    • 10.1.11. Purified Exosome Product (PEP) from RION

11. DIAGNOSTIC APPLICATIONS OF EXOSOMES

  • 11.1. Advantages in Diagnostic Applications
  • 11.2. Major Indications Focused for Diagnosis
  • 11.3. Most Common Targeted Exosome Biomarkers
    • 11.3.1. Exosomal Proteins for Diagnostic Applications
    • 11.3.2. Exosomal miRNAs as Cancer Diagnostic Agents
  • 11.4. Diagnostic Exosome Research
  • 11.5. Key Players in the Development of Exosome Diagnostics
    • 11.5.1. LiquidScan from BioFluidica
    • 11.5.2. ExoEnrich from ExoCan
    • 11.5.3. ExoDx Prostate Test from Exosome Diagnostics, Inc.
    • 11.5.4. TauSome Test from Exosome Sciences
    • 11.5.5. Cancer Diagnosis from Exosomics S.p.A
    • 11.5.6. Guardant360 CDx from Guardant Health
    • 11.5.7. Liver Cancer Detection study by Mursla Bio
    • 11.5.8. BDE Biomarker Assay from NanoSomiX
    • 11.5.9. ExoScreen Assay from Theoria Science

12. APPLICATIONS OF EXOSOMES IN AESTHETICS

  • 12.1. Aesthetic Exosome Treatments
    • 12.1.1. Exosomes in Facial Rejuvenation
    • 12.1.2. Exosomes in Hair Restoration
    • 12.1.3. Exosomes in Scar Reduction
    • 12.1.4. Exosomes in Breast Augmentation
  • 12.2. Sources of Exosomes for Aesthetic Use
  • 12.3. Science behind Dermatologically Relevant Exosomes
  • 12.4. Key Players & Products
  • 12.5. Popular Exosome-Based Aesthetics
    • 12.5.1. AnteAGE Pro System
    • 12.5.2. ExoCR from Cartessa
    • 12.5.3. ELEVAI enfinity from ELEVAI Labs
    • 12.5.4. EXO PLUS from Exoceuticals
    • 12.5.5. Vive from Kimera Labs
    • 12.5.6. CALM Serum from RION Aesthetics
    • 12.5.7. ASCE Exosomes from ExoCoBio

13. DEALS AND FUNDRAISING IN EXOSOME SPACE

  • 13.1. Venture Capital Funding for Exosome companies
    • 13.1.1. EXO Biologics
    • 13.1.2. Exogenus Therapeutics
    • 13.1.3. INEXOPLAT
    • 13.1.4. Mantra Bio
    • 13.1.5. Anjarium Biosciences
    • 13.1.6. Evox Therapeutics, Ltd.
    • 13.1.7. ILIAS Biologics
    • 13.1.8. ExoCoBio, Inc.
    • 13.1.9. Aegle Therapeutics
    • 13.1.10. Evox Therapeutics
    • 13.1.11. Evox Therapeutics
    • 13.1.12. Codiak BioSciences
    • 13.1.13. Codiak BioSciences
    • 13.1.14. Exosome Diagnostics
    • 13.1.15. Exosome Diagnostics, Inc
  • 13.2. Partnership Deals in Exosome Space
    • 13.2.1. Cytiva & Rooster Bio
    • 13.2.2. SomesTech & ConvEyXO
    • 13.2.3. RoosterBio, Inc. & FUJIFILM Diosynth Biotechnologies
    • 13.2.4. Evox Therapeutics & Eli Lilly
    • 13.2.5. Exopharm & Astellas
    • 13.2.6. Univercells Technologies & RoosterBio
    • 13.2.7. AgeX Therapeutics & UCI
    • 13.2.8. VivaZome & La Trobe University
    • 13.2.9. Evotec SE & Curexsys GmbH
    • 13.2.10. Bio-Techne & QIAGEN
    • 13.2.11. InnoCan Pharma & Recipharms
    • 13.2.12. Codiak BioSciences & Sarepta
    • 13.2.13. Evox Therapeutics & Takeda
    • 13.2.14. PureTech & Roche
    • 13.2.15. Evox Therapeutics & Boehringer Ingelheim
    • 13.2.16. Sarpeta Therapeutics & Codiak Biosciences
    • 13.2.17. Navigo Proteins & MDimune
    • 13.2.18. Jazz Pharmaceuticals & Codiak BioSciences
    • 13.2.19. Exosome Diagnostics & Intezyne
    • 13.2.20. Evox Therapeutics & Boehringer Ingelheim
  • 13.3. Acquisition Deals
    • 13.3.1. ExoCoBio & BENEV
    • 13.3.2. Evox Therapeutics & Codiak Biosciences' Technology
    • 13.3.3. Lonza & Exosomics
    • 13.3.4. Lonza & Codiak Biosciences
    • 13.3.5. Bio-Techne Corporation & Exosome Diagnostics
    • 13.3.6. Lonza & HansaBioMed
  • 13.4. Licensing Deals
    • 13.4.1. EVerZom & Erganeo
    • 13.4.2. Elevai Labs & Yuva Biosciences
    • 13.4.3. TOPPAN & Dai Nippon Toryo
    • 13.4.4. Carnegie Mellon University (CMU) & Coya Therapeutics
    • 13.4.5. INOVIQ, Ltd. & ResearchDx, Inc.
    • 13.4.6. ATUM & Codiak BioSciences
    • 13.4.7. Johns Hopkins University & Capricor Therapeutics
    • 13.4.8. Evox Therapeutics & Eli Lily
    • 13.4.9. Codiak BioSciences & Sarepta
    • 13.4.10. VivaZome Therapeutics & University of Adelaide
    • 13.4.11. Evox Therapeutics & Takeda
    • 13.4.12. CEVEC & Evox Therapeutics
    • 13.4.13. Orgenesis & Excella Bio
    • 13.4.14. System Biosciences & QIAGEN
    • 13.4.15. PureTech Health & 3D Biotechnologies
  • 13.5. IPO
    • 13.5.1. Elevai Labs
    • 13.5.2. Codiak Biosciences
    • 13.5.3. Codiak Biosciences
    • 13.5.4. Codiak BioSciences

14. EXOSOME MARKET ANALYSIS

  • 14.1. Market for Exosome Therapeutics
  • 14.2. The Global Market for Ready-to-Use Purified Exosomes by Type
    • 14.2.1. Market Size of Exosomes by Parent Cell Type
  • 14.3. Market for Exosome Diagnostics
  • 14.4. Global Exosome Technologies Market by Product Type
  • 14.5. Global Exosome-Based Aesthetics (Cosmeceuticals) Market
  • 14.6. The Overall Market for Exosomes
  • 14.7. The Market Driver of Exosome Therapies

15. PROFILES OF EXOSOME MARKET COMPETITORS

  • 15.1. 101 Bio
    • 15.1.1. PureExo Exosome Isolation Kit
  • 15.2. Abbexa, Ltd.
  • 15.3. AcouSort AB
    • 15.3.1. Technology: Acoustic Separation
    • 15.3.2. EIC Award
  • 15.4. Aegle Therapeutics
    • 15.4.1. Research & Development
  • 15.5. Aethlon Medical, Inc.
    • 15.5.1. Hemopurifier
  • 15.6. Akrivis Health Care Pvt., Ltd.
  • 15.7. AM BioTech
    • 15.7.1. Bio-Pulsed Technology
    • 15.7.2. ExoGiov
    • 15.7.3. LA EXO Exosome Cosmetics
  • 15.8. AMS Biotechnology, Ltd. (AMSBIO)
  • 15.9. AnteAGE
    • 15.9.1. At-Home Skincare Products
    • 15.9.2. At-Home Brow & Lash Products
    • 15.9.3. VRS Box (6 Pack) [$150]
    • 15.9.4. Professional Skincare Products
    • 15.9.5. Growth Factor Microneedling Products
    • 15.9.6. Stem Cell Facial Microchanneling Products
    • 15.9.7. Medical Skin Care Products
    • 15.9.8. Growth Factor Skin Treatment Products
    • 15.9.9. Growth Factor Hair Regeneration Products
  • 15.10. Aposcience AG
    • 15.10.1. Wound Healing
    • 15.10.2. Myocardial Infarction
  • 15.11. Aruna Bio
    • 15.11.1. AB126 (Neural Exosome)
  • 15.12. BENEV Company, Inc. (ExoCoBio)
    • 15.12.1. Exosome Regenerative Complex
    • 15.12.2. Exosome Regenerative Complex +
    • 15.12.3. EXO-XOM Facial
  • 15.13. BioCat GmbH
    • 15.13.1. ExoQuick Exosome Precipitation
    • 15.13.2. Exosome RNA & DNA Purification
    • 15.13.3. Exosome RNA Amplification & Profiling
    • 15.13.4. Exosome Quantification
    • 15.13.5. Exosome Antibody Array
    • 15.13.6. ExoGlow EV Labeling Kits
    • 15.13.7. Exosome Engineering
  • 15.14. BioFluidica
    • 15.14.1. LiquidScan
    • 15.14.2. Exosome Isolation
  • 15.15. Biological Dynamics, Inc.
    • 15.15.1. Verita Technology
    • 15.15.2. ExoVerita Pro Exosome Enrichment Platform
    • 15.15.3. Exosome Isolation & Analysis Services
  • 15.16. Biorbyt, Ltd.
  • 15.17. Bioscience Institute
    • 15.17.1. Bioscience Clinic Middle East
    • 15.17.2. Bioscience Genomics
    • 15.17.3. Services
      • 15.17.3.1. ExoSkin Therapy
      • 15.17.3.2. ExoHair Therapy
      • 15.17.3.3. ExoJoints Therapy
      • 15.17.3.4. ExoMale Therapy
      • 15.17.3.5. ExoFemale Therapy
      • 15.17.3.6. XOLINE Exosome Cosmetics
  • 15.18. Biosynth International, Inc.
    • 15.18.1. ME Kit (Microvesicle Extraction Kit)
  • 15.19. BreStem Therapeutics, Inc.
  • 15.20. Capricor Therapeutics
    • 15.20.1. Portfolio
    • 15.20.2. StealthX Technology
  • 15.21. Carmine Therapeutics
    • 15.21.1. REGENT Platform
  • 15.22. Cellarcus Biosciences, Inc.
    • 15.22.1. vFC Vesicle Analysis Assays
    • 15.22.2. vTAG Antibodies
    • 15.22.3. Vesicles and Vesicle Assay Standards
  • 15.23. Cell Care Therapeutics
    • 15.23.1. CCT-101
  • 15.24. Cells for Cells
    • 15.24.1. Current Clinical Trial using Exosomes
  • 15.25. Cell Guidance Systems, Ltd.
    • 15.25.1. Exosome Products
    • 15.25.2. Exo-spin Purification
    • 15.25.3. ExoLISA Technology: Exosome Detection
    • 15.25.4. Exosome Validated Antibodies
    • 15.25.5. Instant Exosomes
    • 15.25.6. NTA Size Profiling Service
  • 15.26. Ciloa
    • 15.26.1. Antibodies against Undruggable Targets
    • 15.26.2. Adjuvant & Virus-Free Vaccines
    • 15.26.3. Virus-Free Therapeutic Vectors
    • 15.26.4. Technology
  • 15.27. ConvEyXO
    • 15.27.1. Exo-Harvest Technology
    • 15.27.2. XomeXBio Technology
  • 15.28. Craif, Inc.
    • 15.28.1. NANO IP (Nano Intelligence Platform)
  • 15.29. Creative Bioarray
    • 15.29.1. Exosome Antibodies
    • 15.29.2. Exosome DNA-RNA Extraction Kits
    • 15.29.3. Exosome Isolation Tools
    • 15.29.4. Exosome Standards
    • 15.29.5. Fluorescent Exosome Standards
    • 15.29.6. Liquid Biopsy
    • 15.29.7. Exosome Research Services
  • 15.30. Creative Biostructure
    • 15.30.1. Exosome Products
    • 15.30.2. Exosome Services
      • 15.30.2.1. Exosome Isolation Services
      • 15.30.2.2. Exosome Analysis Services
      • 15.30.2.3. Exosome Characterization Services
      • 15.30.2.4. Exosome Engineering Services
      • 15.30.2.5. Exosome In Vitro Functional Assay
      • 15.30.2.6. Exosome In Vitro Functional Assay
  • 15.31. Creative Biolabs
    • 15.31.1. Exosome Products
    • 15.31.2. Exosome Isolation Tools
    • 15.31.3. Exosome Capture & Quantification Kits
    • 15.31.4. Exosome Antibody Products
    • 15.31.5. Exosome Standards
    • 15.31.6. Exosome Labeling Kits
    • 15.31.7. Exosomes Surface Modification Kits
    • 15.31.8. Exosome Identification Kits
    • 15.31.9. Exosome Marker cDNA Plasmid Products
    • 15.31.10. Exosome Release Modulation Reagents
    • 15.31.11. LipidSync Exosomes
    • 15.31.12. Exosome Services
  • 15.32. Creative Medical Technology Holdings, Inc.
    • 15.32.1. AmnioStem Stroke Therapy
  • 15.33. Creative Proteomics
    • 15.33.1. Exosome Services
  • 15.34. CUSABIO Technology LLC
    • 15.34.1. Exosome Isolation Kits
  • 15.35. Diadem Biotherapeutics
    • 15.35.1. Technology
  • 15.36. Direct Biologics
    • 15.36.1. ExoFlo
    • 15.36.2. AmnioWrap
  • 15.37. Elevai Labs, Inc.
    • 15.37.1. ELEVAI enfinity
    • 15.37.2. ELEVAI empower
    • 15.37.3. ELEVAI Root Renewal System
  • 15.38. Entelexo Biotherapeutics
  • 15.39. EriVan Bio
    • 15.39.1. Services
    • 15.39.2. Research Products
  • 15.40. EVerZom
    • 15.40.1. EVerZom Platform
  • 15.41. Evolutionary Biologics, Inc.
    • 15.41.1. EXO ELIXIR
    • 15.41.2. EVO GROW
    • 15.41.3. EVO JEL
    • 15.41.4. EXO RNA
    • 15.41.5. EVO HYBRID
    • 15.41.6. EXO PERIO
  • 15.42. Evomic Science LLC
    • 15.42.1. ExoEZ Exosome Isolation Kit
  • 15.43. Evox Therapeutics, Ltd.
    • 15.43.1. Gene Therapy
    • 15.43.2. Gene Editing
    • 15.43.3. RNA Therapeutics
    • 15.43.4. Precision Therapeutic Targeting
    • 15.43.5. Protein Therapeutics
    • 15.43.6. Manufacturing Exosomes
    • 15.43.7. Focus on Rare Diseases
  • 15.44. EXO Biologics
    • 15.44.1. Lead Product Candidate
  • 15.45. ExoCan Healthcare Technologies Pvt., Ltd.
    • 15.45.1. ExoEnrich
    • 15.45.2. ExoEngineering
    • 15.45.3. SAC-3D
    • 15.45.4. Services
      • 15.45.4.1. Multiphenotype Screen
      • 15.45.4.2. Small Molecule Screening
      • 15.45.4.3. Exo-BiDD
  • 15.46. Exocel Bio
    • 15.46.1. Services
      • 15.46.1.1. Exosome Isolation via Ultracentrifugation
      • 15.46.1.2. Nanoparticle Analysis for Size Distribution and Concentration
      • 15.46.1.3. Custom Experiments with NTA
      • 15.46.1.4. Custom Growth Factors Production
    • 15.46.2. Products
      • 15.46.2.1. Exovex REVIVE
      • 15.46.2.2. Exovex RENEW
      • 15.46.2.3. Exovex REVEAL
      • 15.46.2.4. Exovex REFINE
      • 15.46.2.5. Exovex RESTORE
      • 15.46.2.6. Exovex EQUUSOME
      • 15.46.2.7. Exovex CANISOME
      • 15.46.2.8. Exovex FELISOM
  • 15.47. Exogenus Therapeutics
    • 15.47.1. Exo-101
    • 15.47.2. ExoWound
  • 15.48. Exokeryx, Inc.
    • 15.48.1. Demeter EVPrep
    • 15.48.2. ExoScan
  • 15.49. ExoProTher Medical
  • 15.50. ExoQure
    • 15.50.1. Technology
    • 15.50.2. Products
  • 15.51. EXORPHIA, Inc.
    • 15.51.1. Activation Technology to produce Prime-EV
    • 15.51.2. Modification Technology to Produce Smart-EV
    • 15.51.3. INPACT-EV Technology
    • 15.51.4. EV Analysis Technology: EV-QUEST
    • 15.51.5. EXORPHIA's Product Pipeline
  • 15.52. ExosomeDx (biotechne)
    • 15.52.1. ExoDx Prostate Test
    • 15.52.2. Pharma Services
    • 15.52.3. Biomarker Discovery Services
  • 15.53. ExosomePlus
    • 15.53.1. MSC-Derived Exosomes
    • 15.53.2. ExoCope Technology
  • 15.54. Exosome Sciences
    • 15.54.1. TauSome (Exosomal Tau) Biomarker
  • 15.55. ExoStemTech Co., Ltd.
    • 15.55.1. Cartisome
    • 15.55.2. EST-T-EXO
    • 15.55.3. Hepatosome
    • 15.55.4. Hypoxisome
    • 15.55.5. Exosome Manufacturing Platform
    • 15.55.6. Protein Loading & Delivery Platform
  • 15.56. ExoVectory
    • 15.56.1. Technology
    • 15.56.2. Therapeutic Areas Focused
    • 15.56.3. Exosome Immunotherapy for Cancer
    • 15.56.4. Exosome Gene Therapy
  • 15.57. ExSURE Pvt. Ltd.
  • 15.58. Florica Therapeutics
  • 15.59. HansaBioMed Life Sciences, Ltd.
    • 15.59.1. Products
    • 15.59.2. Services
  • 15.60. ILIAS Biologics, Inc.
    • 15.60.2. Cargo Loading Process
    • 15.60.3. Exo-Target: Platform Technology
  • 15.61. INEXOPLAT, Inc.
  • 15.62. Innocan Pharma
    • 15.62.1. Cannabidiol (CBD)-Loaded Exosomes
  • 15.63. Innovex Therapeutics, SL
    • 15.63.1. Research & Development
    • 15.63.2. Vaccine against Plasmodium vivax malaria (PvRexVac)
    • 15.63.3. Vaccine against COVID-19 (ExoCoVac)
    • 15.63.4. Vaccine against PRRSV (PrrsvExoVac)
  • 15.64. INOVIQ, Ltd.
    • 15.64.1. NETs Technology
    • 15.64.2. EXO-NET Pan Exosome
  • 15.65. Irazu Oncology
  • 15.66. Izon Science, Ltd.
    • 15.66.1. qEV Isolation
    • 15.66.2. qEV Automation
    • 15.66.3. qEV Zenco
    • 15.66.4. Robotic System for Diagnostic Development
    • 15.66.5. qEV Magnetic Concentration Kit
    • 15.66.6. Tunable Resistive Pulse Sensing (TRPS)
  • 15.67. Kimera Labs, Inc.
    • 15.67.1. Vive
    • 15.67.2. Luxir & Luxir+
  • 15.68. Leading Biology, Inc.
  • 15.69. LifeSpan Biosciences, Inc.
  • 15.70. Lonza Group, Ltd.
    • 15.70.1. Exosome Service
  • 15.71. Mantra Bio
    • 15.71.1. REVEAL
    • 15.71.2. Partnering
  • 15.72. Mercury Bio
    • 15.72.1. The Chimeric yEV System
  • 15.73. Mercy Bioanalytics
    • 15.73.1. The Mercy Halo Test
  • 15.74. Micregen, Ltd.
    • 15.74.1. Secretomix
  • 15.75. Microgentas
    • 15.75.1. Products
      • 15.75.1.1. Exo TFF
      • 15.75.1.2. ExoFilter
      • 15.75.1.3. ExoCAS-2 (Exosome Clustering and Scattering)
      • 15.75.1.4. ExoPAS Advanced (Exosome Precipitation and Scattering)
      • 15.75.1.5. miRQuick (Exosomal miRNA)
      • 15.75.1.6. PIBEX System
      • 15.75.1.7. Plant Exosomes for Cosmetics
      • 15.75.1.8. Centella Asiatica Extracellular Vesicles (CICA EVs)
    • 15.75.2. Services
  • 15.76. miR Scientific
    • 15.76.1. miR Sentinel
  • 15.77. Mursla Bio
    • 15.77.1. Liver EV Liquid Biopsy Platform
  • 15.78. MyBioSource, Inc.
  • 15.79. Nano 24 (OBCDCT24)
  • 15.80. NanoSomiX, Inc.
    • 15.80.1. Technology
  • 15.81. Nanovex Biotechnologies
    • 15.81.1. Technology
    • 15.81.2. Synthetic Exosomes
  • 15.82. NeurExo Sciences
    • 15.82.1. Research & Development Programs
  • 15.83. NeuroDex, Inc.
    • 15.83.1. ExoSORT
    • 15.83.2. Lumin-EV
    • 15.83.3. Alpha-synuclein Assay
    • 15.83.4. TDP43 Assay
    • 15.83.5. Synaptic Protein Assay
    • 15.83.6. Autophagy Assay
    • 15.83.7. Biomarker Discovery Services
    • 15.83.8. LuminEV Kit
  • 15.84. Norgen Biotek Corporation
    • 15.84.1. Exosome Kits
      • 15.84.1.1. Intact Exosome Purification
      • 15.84.1.2. RNA Isolation from Intact Exosomes
      • 15.84.1.3. Exosome Purification, Exosome RNA and Free-Circulating RNA Isolation
      • 15.84.1.4. RNA Isolation from Purified Intact Exosomes
      • 15.84.1.5. Exosome Depletion
      • 15.84.1.6. Exosome Labeling and Cleaning Kit
      • 15.84.1.7. Isolation Services
      • 15.84.1.8. Contract Manufacturing Services
  • 15.85. Novaxomx GmbH
    • 15.85.1. Technology
  • 15.86. Novus Biologicals
    • 15.86.1. Exosome Research Tools
  • 15.87. NurExone Biologic, Inc.
    • 15.87.1. ExoTherapy
  • 15.88. Oasis Diagnostics Corporation
    • 15.88.1. Pure.SAL
  • 15.89. NX Prenatal, Inc.
    • 15.89.1. Technology
  • 15.90. OmniSpirant Therapeutics
    • 15.90.1. OmniSome Therapeutic Platform
  • 15.91. OncoXome, Inc.
    • 15.91.1. OncoXome's Exosomes
  • 15.92. Paracrine Therapeutics Pte, Ltd.
    • 15.92.1. Science
  • 15.93. QIAGEN
    • 15.93.1. exoEasy Maxi Kit
    • 15.93.2. exoRNeasy Midi Kit
    • 15.93.3. mercury LNA miRNA Focus PCR Panels
    • 15.93.4. miRCURY Exosome Serum/Plasma Kit
  • 15.94. Reactive Medical Labs
  • 15.95. ReNeuron
    • 15.95.1. CustomEX - A Customizable Exosome Platform
  • 15.96. RION Aesthetics, Inc.
    • 15.96.1. Products
      • 15.96.1.1. INTENSE Serum
      • 15.96.1.2. DAILY Serum
      • 15.96.1.3. CALM Serum
      • 15.96.1.4. HAIR Serum
  • 15.97. Rivela Diagnostics
    • 15.97.1. Technology
  • 15.98. RoosterBio, Inc.
    • 15.98.1. MSC-derived Exosomes
    • 15.98.2. QuickShip Exosomes
    • 15.98.3. QuickShip MSC and Exosome Media
    • 15.98.4. XF Bioreactor MSC & EV Development Kits
    • 15.98.5. XF Bioreactor MSC & EV Scale-Up Kits
    • 15.98.6. XF Bioreactor MSC & EV Starter Kits
    • 15.98.7. RoosterCollect-EV-CC
  • 15.99. ShiftBIO
    • 15.99.1. NSM Platform Technology
  • 15.100. SOL Bio Corporation
    • 15.100.1. Business Model
    • 15.100.2. NeutraRelease Technology
    • 15.100.3. ExoMain
    • 15.100.4. ExoBead
  • 15.101. SomesTech
    • 15.101.1. Products & Solutions
      • 15.101.1.1. ExoNP
      • 15.101.1.2. ExoLoad
      • 15.101.1.3. AI + DDS
  • 15.102. Stem Cell Medicine, Ltd.
    • 15.102.1. SCM's Pipeline
  • 15.103. System Biosciences
    • 15.103.1. Products
      • 15.103.1.1. Exosome Isolation Products
      • 15.103.1.2. Exosome Detection Products
      • 15.103.1.3. Exosome Quantitation Products
      • 15.103.1.4. Exosome Labeling Kit Products
      • 15.103.1.5. Exosome Biomarker Discovery Products
      • 15.103.1.6. Exosome Engineering & Design Products
    • 15.103.2. Services
  • 15.104. Theoria Science, Inc.
    • 15.104.1. ExoScreen Technology
  • 15.105. TheraXyte
    • 15.105.1. TAXY - A Programmable Drug Delivery System
  • 15.106. Thermo Fisher Scientific
    • 15.106.1. Exosome Products for Testing & Research
  • 15.107. TheraXyte Bioscience
    • 15.107.1. TAXY
  • 15.108. The Tiny Cargo Company
  • 15.109. TransGen Biotech, Co., Ltd.
    • 15.109.1. Products
      • 15.109.1.1. TransExo Cell Media Exosome Kit
      • 15.109.1.2. TransExo Urine Exosome Kit
      • 15.109.1.3. TransExo Serum/Plasma Exosome Kit
      • 15.109.1.4. TransExo Serum/Plasma Exosome Total RNA Extraction Kit
      • 15.109.1.5. TransExo Serum/Plasma Exosome Total miRNA Extraction Kit
  • 15.110. Tymora Analytical
    • 15.110.1. Services
      • 15.110.1.1. Plasma Proteomics (PTMs)
      • 15.110.1.2. Urine Proteomics
      • 15.110.1.3. Saliva Proteomics
      • 15.110.1.4. Tissue Proteomics
  • 15.111. Unicyte AG
    • 15.111.1. Technology
  • 15.112. Urvogelbio Pvt, Ltd.
  • 15.113. Versatope Therapeutics
    • 15.113.1. Technology
    • 15.113.2. Universal Influenza Vaccine
  • 15.114. VesiCURE Therapeutics
    • 15.114.1. modEXO Platform
    • 15.114.2. dilEVery Delivery System
  • 15.115. Vesigen Therapeutics, Inc.
    • 15.115.1. ARMMs
    • 15.115.2. Disease Areas of Focus
      • 15.115.2.1. Ocular
      • 15.115.2.2. Immunology
      • 15.115.2.3. Neurology
      • 15.115.2.4. Hematology
  • 15.116. VivaZome Therapeutics
    • 15.116.1. VivaZome's Clinical Targets
  • 15.117. ZEO ScientifiX, Inc.
    • 15.117.1. Aesthetic Exosomes
    • 15.117.2. PPX
  • 15.118. Xosomix

INDEX OF FIGURE

  • FIGURE 2.1: Classification of Extracellular Vesicles
  • FIGURE 2.2: Exosome Formation
  • FIGURE 2.3: Exosome Uptake by Target Cells
  • FIGURE 2.4: Structure of an Exosome
  • FIGURE 2.5: Membrane Lumen Components of Exosomes
  • FIGURE 2.6: Classification of Exosomes by Origin
  • FIGURE 2.7: Exosome Isolation Methods
  • FIGURE 2.8: Exosomes with Loaded Therapeutics in the Lumen and Surface Display
  • FIGURE 3.1: Pre-Isolation Interior Modification Methods
  • FIGURE 3.2: Post-Isolation Interior Modification Methods
  • FIGURE 3.3: Surface Modification through Parent Cell
  • FIGURE 3.4: Direct Surface Modification
  • FIGURE 3.5: Pre-Isolation Interior Modification Methods
  • FIGURE 3.6: Post-Isolation Interior Modification Methods
  • FIGURE 3.7: An Engineered Exosome showing Surface and Interior Modifications
  • FIGURE 4.1: Number of PubMed.gov Publications, 2000-2024
  • FIGURE 4.2: Publication Trends of Exosome Diagnostics and Therapeutics
  • FIGURE 4.3: Number of PubMed Papers on Exosome Cargo-Loading by Technology
  • FIGURE 4.4: PubMed Papers on Exosome Isolation & Purification by Technology
  • FIGURE 4.5: PubMed Papers on Lipid Nanoparticles and Exosomes as Drug Carriers
  • FIGURE 4.6: Distribution of Exosome Publications by Disease Type
  • FIGURE 4.7: Exosome Publications by Cancer Type
  • FIGURE 5.1: Exosome Patent Publications over Time, 2000-June 2024
  • FIGURE 5.2: Exosome Patents: Therapeutic vs. Diagnostics
  • FIGURE 5.3: Exosome Patents/Patent Applications by Exosome Sources
  • FIGURE 5.4: Patents/Patent Applications by Isolation-Preparation Technologies
  • FIGURE 5.5: Patents/Patent Applications by Type of Cargo
  • FIGURE 5.6: Patents/Patent Applications by Cargo Loading Methods
  • FIGURE 5.7: Patents/Patent Applications by Therapy Area
  • FIGURE 5.8: Leading Assignees of Exosome Patents
  • FIGURE 5.9: Top Five Countries with Exosome Patents
  • FIGURE 6.1: Percent Share of Clinical Trials by Application
  • FIGURE 7.1: Schematic of Differential Ultracentrifugation
  • FIGURE 7.2: Schematic of Density Gradient Ultracentrifugation
  • FIGURE 7.3: Schematic of Tandem Configured Ultrafiltration
  • FIGURE 7.4: Sequential Ultrafiltration
  • FIGURE 7.5: Schematic of Size Exclusion Chromatography
  • FIGURE 7.6: Schematic of Polymer Precipitation Method
  • FIGURE 7.7: Schematic of Immunoaffinity Capture Method
  • FIGURE 7.8: Diagram of Working Principle of Microfluidic Device
  • FIGURE 9.1: Schematic of Incubation Method of Drug Loading
  • FIGURE 9.2: Schematic of Transfection Method
  • FIGURE 9.3: Schematic Illustration of Sonication Method
  • FIGURE 9.4: Schematic Illustration of the Principle of Electroporation
  • FIGURE 9.5: Schematic Illustration of Drug Loading by Extrusion Method
  • FIGURE 9.6: Schematic Illustration of Genetic Modification of Exosome
  • FIGURE 10.1: Schematic Illustration of the Structure of EXO-CD24
  • FIGURE 10.2: Aethlon's Hemopurifier
  • FIGURE 10.3: Ciola's Unique in vivo Technology
  • FIGURE 10.4: Schematic of EXPLOR
  • FIGURE 10.5: CNS Specificity of AB126
  • FIGURE 10.6: OmniSomes from OmniSpirant
  • FIGURE 10.7: EXO-101 from Exogenus
  • FIGURE 11.1: Great Things in Tiny Packages
  • FIGURE 11.2: Major Indications Focused for Diagnosis
  • FIGURE 11.3: LiquidScan from BioFluidica
  • FIGURE 11.4: Exosome Isolation by ExoEnrich
  • FIGURE 11.5: Features of ExoDx Prostate Test
  • FIGURE 11.6: ExoScreen Assay from Theoria Science
  • FIGURE 12.1: Exosomes in Facial Rejuvenation using DermaPen
  • FIGURE 12.2: Exosome Therapy for Hair Restoration
  • FIGURE 12.3: Exosomes in Scar Reuction
  • FIGURE 12.4: AnteAGE Pro System
  • FIGURE 12.5: ExoCR from Cartessa
  • FIGURE 12.6: ELEVAI enfinity
  • FIGURE 12.7: EXO PLUS from Exoceuticals
  • FIGURE 12.8: Vive from Kimera Labs
  • FIGURE 12.9: CALM Serum from RION Aesthetics
  • FIGURE 12.10: ASCE Exosomes from ExoCoBio
  • FIGURE 14.1: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
  • FIGURE 14.2: Global Market for Ready-to-Use Exosomes by Type, 2023
  • FIGURE 14.3: Global Exosome Therapy Market by Parent Cell Type, 2023
  • FIGURE 14.4: Global Market for Exosome Diagnostics by Geography, 2023-2031
  • FIGURE 14.5: Global Exosome Technologies Market by Products, 2023-2031
  • FIGURE 14.6: Global Market for Exosome-based Aesthetic Products by Segment
  • FIGURE 14.7: The Overall Exosome Market by Segment, 2031
  • FIGURE 15.1: Aethlon's Hemopurifier
  • FIGURE 15.2: qEV Zenco for Therapeutic Development
  • FIGURE 15.3: Robotic System for Diagnostic Development

INDEX OF TABLES

  • TABLE 2.1: Number of Molecular Contents identified in Exosomes
  • TABLE 2.2: Proteins Identified in Exosomes
  • TABLE 2.3: Common Lipid Contents of Exosomes
  • TABLE 2.4: Nucleic Acids Present in Cancer-Derived Exosomes
  • TABLE 2.5: Types of Therapeutic Cargos Loaded into Exosomes
  • TABLE 2.6: Differences between Cell Therapy and Exosome Therapy
  • TABLE 3.1: Hydrophobic Cargo Incorporated in Exosome Mmbrane
  • TABLE 3.2: Examples of Hydrophilic Cargo Loaded into Exosome Lumen
  • TABLE 5.1: Exosome Patent Applications by Jurisdiction as of June 23, 2024
  • TABLE 5.2: Exosome Patent Applicants
  • TABLE 5.3: Exosome Patent Inventors
  • TABLE 5.4: Exosome Patent Owners
  • TABLE 5.5: Legal Status of Exosome Patents as of June 22, 2024
  • TABLE 6.1: Exosome Clinical Trials by Phase of Study
  • TABLE 6.2: Exosome Clinical Trials by Funder Type
  • TABLE 6.3: Exosome Clinical Trials by Technology
  • TABLE 6.4: Current Status of Clinical Trials using Exosomes in Treating Diseases
  • TABLE 6.5: Clinical Trials using Exosomes for Diagnostic Studies
  • TABLE 6.6: Major Exosome R&D Companies
  • TABLE 6.7: Exosome Therapeutics in Preclinical Development
  • TABLE 8.1: Exosome Technology Platforms Developed by Commercial Companies
  • TABLE 10.1: Key Players in Therapeutic Exosome Research
  • TABLE 11.1: Most Common Targeted Exosome Biomarkers
  • TABLE 11.2: Exosomal Proteins for Diagnostic Applications
  • TABLE 11.3: Exosomal miRNAs as Cancer Diagnostic Agents
  • TABLE 11.4: A Sample of Exosome Diagnostic Clinical Trials
  • TABLE 11.5: Key Players in the Development of Exosome Diagnostics
  • TABLE 12.1: Key Players in Exosome-based Aesthetics
  • TABLE 13.1: Venture Capital Funding raised by Exosome Companies
  • TABLE 13.2: Partnership/Collaboration Deals in Exosome Space
  • TABLE 13.3: Acquisition Deals in Exosome Space
  • TABLE 13.4: Licensing Deals in Exosome Space
  • TABLE 13.5: Exosome Companies raising IPO Funds
  • TABLE 14.1: Likely-to-be Approved Exosome Therapeutics between 2026 and 2029
  • TABLE 14.2: Market for the Likely-to-be Approved Exosome Therapeutics, 2029-2035
  • TABLE 14.3: Global Market for Ready-to-Use Exosomes by Type, 2023-2031
  • TABLE 14.4: Global Exosome Therapy Market by Parent Cell Type, 2023-2031
  • TABLE 14.5: Global Market for Exosome Diagnostics by Geography, 2023-2031
  • TABLE 14.6: Global Exosome Technologies Market by Products, 2023-2031
  • TABLE 14.7: Global Market for Exosome-based Aesthetic Products by Segment
  • TABLE 14.8: The Overall Market for Exosomes
  • TABLE 15.1: Aegle's Product Pipeline
  • TABLE 15.2: Aruna Bio's Product Pipeline
  • TABLE 15.3: BreStem Therapeutics' Product Pipeline
  • TABLE 15.4: Capricor's Multi-Stage Pipeline
  • TABLE 15.5: Entelexo's Pipeline
  • TABLE 15.6: Evox Therapeutics' Product Pipeline
  • TABLE 15.7: EXO Biologic's Product Pipeline
  • TABLE 15.8: EXORPHIA's Product Pipeline
  • TABLE 15.9: ExoStemTech's Pipeline Products
  • TABLE 15.10: ILIAS' Product Pipeline
  • TABLE 15.11: INOVIQ's Development Pipeline
  • TABLE 15.12: NeurExo's Research & Development Programs
  • TABLE 15.13: NeuroDex's Pipeline
  • TABLE 15.14: ShiftBIO's Natural Drug Delivery Platform-based Programs
  • TABLE 15.15: Unicyte's Pipeline